{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:07:26Z","timestamp":1765976846163,"version":"3.41.2"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sigrid Juselius Foundation","award":["1726"],"award-info":[{"award-number":["1726"]}]},{"name":"Finnish Governmental Funding for Health Science Research","award":["TYH2021314"],"award-info":[{"award-number":["TYH2021314"]}]},{"name":"The University of Helsinki Doctoral School"},{"name":"Finnish Multidisciplinary Centre of Excellence in Antimicrobial Resistance Research"},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["346127"],"award-info":[{"award-number":["346127"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Travel to low- and middle-income countries (LMICs) increases the risk of urinary tract infections (UTIs), including those caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE). Focusing on international travel, we explored resistance profiles of urinary ESBL-PE and non-ESBL-PE isolates in a low antimicrobial resistance prevalence country and factors associated with UTI treatment failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>During 2015\u201319, we recruited 18\u201365-year-old individuals with recent ESBL-PE UTI and a respective cohort of those with non-ESBL-PE UTI to complete questionnaires on symptoms, antibiotic therapies and treatment failure risk factors. We compared uropathogens\u2019 resistance profiles amongst patients with or without LMIC travel history and conducted multivariable analyses to identify factors contributing to mismatching antimicrobial treatment (uropathogen resistant to the initial antimicrobial used) and clinical failure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Amongst non-ESBL-PE UTI patients (n\u2009=\u2009187), trimethoprim resistance was more common in isolates from individuals with recent LMIC travel (8\/19, 42.1%) compared to those without (30\/167, 18.0%) [odds ratio (OR) 3.3, compatibility interval (CI) 95% 1.2\u20139.0]. ESBL-PE isolates (n\u2009=\u2009130) showed no differences in resistance profiles with respect to LMIC travel history.<\/jats:p>\n                  <jats:p>In the group non-ESBL-PE UTI, risk factors included microbiological mismatching recent LMIC travel [adjusted odds ratio (AOR) 3.6, CI 95% 1.0\u201312.7] and travellers\u2019 diarrhoea (AOR 7.1, CI 95% 1.1\u201345.6); no factors were significantly associated with mismatching in the group ESBL-PE UTI. As risk factors for clinical failure, in the group non-ESBL-PE UTI, we identified microbiological mismatching (AOR 15.2, CI 95% 4.0\u201357.9), and renal\/bladder disease (AOR 5.2, CI 95% 1.1\u201323.2), and in the group ESBL-PE UTI, microbiological mismatching (AOR 8.1, CI 95% 2.6\u201324.7).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>LMIC travel increases the risk of nonmatching empiric antimicrobials, concurring with increased trimethoprim resistance rates amongst the non-ESBL-PE isolates. Our data suggest that UTI patients with recent LMIC travel should not be empirically treated with trimethoprim and, when possible, urinary culturing is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taaf025","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:45:28Z","timestamp":1743363928000},"source":"Crossref","is-referenced-by-count":1,"title":["Travel to low- and middle-income countries and travellers\u2019 diarrhoea increase risk of mismatching antimicrobial therapy for urinary tract infection"],"prefix":"10.1093","volume":"32","author":[{"given":"Anu","family":"Patjas","sequence":"first","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital , FI-00029 HUS Helsinki ,","place":["Finland"]},{"name":"Human Microbiome Research Unit, University of Helsinki , Haartmaninkatu 3, FI-00290 Helsinki,","place":["Finland"]},{"name":"Finnish Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, FIMAR, University of Helsinki , Haartmaninkatu 3, FI-00290 Helsinki,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Kantele","sequence":"additional","affiliation":[{"name":"Meilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, University of Helsinki and Helsinki University Hospital , FI-00029 HUS Helsinki ,","place":["Finland"]},{"name":"Human Microbiome Research Unit, University of Helsinki , Haartmaninkatu 3, FI-00290 Helsinki,","place":["Finland"]},{"name":"Finnish Multidisciplinary Center of Excellence in Antimicrobial Resistance Research, FIMAR, University of Helsinki , Haartmaninkatu 3, FI-00290 Helsinki,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"2025052810022404000_ref1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2025052810022404000_ref2","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2468-2667(22)00225-0","article-title":"The burden of bacterial antimicrobial resistance in the WHO European region in 2019: A cross-country systematic analysis","volume":"7","author":"Mestrovic","year":"2022","journal-title":"Lancet Public Health"},{"key":"2025052810022404000_ref3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: Epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"2025052810022404000_ref4","first-page":"2003","volume-title":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022","author":"Fikri","year":"2022"},{"key":"2025052810022404000_ref5","doi-asserted-by":"crossref","first-page":"102331","DOI":"10.1016\/j.tmaid.2022.102331","article-title":"International travel and travelers\u2019 diarrhea \u2013 Increased risk of urinary tract infection","volume":"48","author":"Patjas","year":"2022","journal-title":"Travel Med Infect Dis"},{"key":"2025052810022404000_ref6","doi-asserted-by":"crossref","first-page":"taad155","DOI":"10.1093\/jtm\/taad155","article-title":"International travel increases risk of urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacterales-three-arm case-control study","volume":"31","author":"Patjas","year":"2024","journal-title":"J Travel Med"},{"key":"2025052810022404000_ref7","doi-asserted-by":"crossref","first-page":"e69581","DOI":"10.1371\/journal.pone.0069581","article-title":"Risk factors for community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae \u2013 A case\u2013control study in a low prevalence country","volume":"8","author":"S\u00f8raas","year":"2013","journal-title":"PloS One"},{"key":"2025052810022404000_ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijid.2015.03.006","article-title":"Urinary tract infections due to extended-spectrum beta-lactamase-producing gram-negative bacteria: Identification of risk factors and outcome predictors in an Australian tertiary referral hospital","volume":"34","author":"Osthoff","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2025052810022404000_ref9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1017\/S0950268817002680","article-title":"Risk factors for acquisition of multidrug-resistant Escherichia coli and development of community-acquired urinary tract infections","volume":"146","author":"Ukah","year":"2018","journal-title":"Epidemiol Infect"},{"key":"2025052810022404000_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciu957","article-title":"Antimicrobials increase travelers\u2019 risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae","volume":"60","author":"Kantele","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025052810022404000_ref11","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/jtm\/taw101","article-title":"Travel-acquired ESBL-producing Enterobacteriaceae: Impact of colonization at individual and community level","volume":"24","author":"Woerther","year":"2017","journal-title":"J Travel Med"},{"key":"2025052810022404000_ref12","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/S2666-5247(20)30224-X","article-title":"Dynamics of intestinal multidrug-resistant bacteria colonisation contracted by visitors to a high-endemic setting: A prospective, daily, real-time sampling study","volume":"2","author":"Kantele","year":"2021","journal-title":"Lancet Microbe"},{"key":"2025052810022404000_ref13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/civ333","article-title":"High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics","volume":"61","author":"Rupp\u00e9","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2025052810022404000_ref14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1473-3099(16)30319-X","article-title":"Import and spread of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): A prospective, multicentre cohort study","volume":"17","author":"Arcilla","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025052810022404000_ref15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/cid\/ciz182","article-title":"Despite predominance of uropathogenic\/extraintestinal pathotypes amongst travel-acquired extended-spectrum \u03b2-lactamase-producing Escherichia coli, the most commonly associated clinical manifestation is travelers\u2019 diarrhea","volume":"70","author":"Kantele","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025052810022404000_ref16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tmaid.2017.01.003","article-title":"Fluoroquinolone antibiotic users select fluoroquinolone-resistant ESBL-producing Enterobacteriaceae (ESBL-PE) \u2013 Data of a prospective traveller study","volume":"16","author":"Kantele","year":"2017","journal-title":"Travel Med Infect Dis"},{"key":"2025052810022404000_ref17","doi-asserted-by":"crossref","first-page":"30074","DOI":"10.2807\/1560-7917.ES.2015.20.47.30074","article-title":"International travel and acquisition of multidrugresistant Enterobacteriaceae: A systematic review","volume":"20","author":"Hassing","year":"2015","journal-title":"Eurosurveillance"},{"key":"2025052810022404000_ref18","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025052810022404000_ref19","first-page":"7","article-title":"EAU guidelines on urological infections. Edn. Presented at the EAU annual congress Milan, Italy","author":"Bonkat","year":"2023","journal-title":"Eur Assoc Urol"},{"key":"2025052810022404000_ref20","doi-asserted-by":"crossref","first-page":"dlae188","DOI":"10.1093\/jacamr\/dlae188","article-title":"Urinary tract infections: A retrospective cohort study of (mis)matching antimicrobial therapy and clinical outcome among Finnish adults","volume":"6","author":"Patjas","year":"2024","journal-title":"JAC-Antimicrobial Resist"},{"key":"2025052810022404000_ref21","article-title":"Urinary tract infections. Current care guidelines","author":"Working group set by the Finnish Medical Society, Duodecim, Finnish Society of Nephrology","year":"2024","journal-title":"Helsinki Finnish Med Soc Duodecim"},{"key":"2025052810022404000_ref22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.15756","article-title":"Guideline of guidelines: Management of recurrent urinary tract infections in women","volume":"130","author":"Kwok","year":"2022","journal-title":"BJU Int"},{"author":"EUCAST. European committee of antimicrobial susceptibility testing","key":"2025052810022404000_ref23"},{"key":"2025052810022404000_ref24","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: A prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J Antimicrob Chemother"},{"year":"2025","author":"World Health Organization","key":"2025052810022404000_ref25"},{"key":"2025052810022404000_ref26","first-page":"22","article-title":"Bakteerien mikrobil\u00e4\u00e4keresistenssi Suomessa: Finres","author":"Ahava","year":"2023","journal-title":"Finnish Inst Heal Welf"},{"key":"2025052810022404000_ref27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkg280","article-title":"Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the pan-European ECO.SENS project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025052810022404000_ref28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2016.05.003","article-title":"Travel to Asia and traveller\u2019s diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum \u03b2-lactamase-producing Enterobacteriaceae-a prospective cohort study","volume":"22","author":"Reuland","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2025052810022404000_ref29","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1128\/AAC.01200-07","article-title":"Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis","volume":"52","author":"Colgan","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052810022404000_ref30","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s15010-019-01361-y","article-title":"Active surveillance of antibiotic resistance patterns in urinary tract infections in primary care in Switzerland","volume":"47","author":"Plate","year":"2019","journal-title":"Infection"},{"key":"2025052810022404000_ref31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/pcan.2016.36","article-title":"Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005\u20132013: A population-based analysis","volume":"19","author":"Lahdensuo","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025052810022404000_ref32","doi-asserted-by":"crossref","first-page":"taz080","DOI":"10.1093\/jtm\/taz080","article-title":"Antibiotic resistance patterns of Escherichia coli in migrants vs non-migrants: A study of 14 561 urine samples","volume":"26","author":"Sloth","year":"2019","journal-title":"J Travel Med"},{"key":"2025052810022404000_ref33","doi-asserted-by":"crossref","first-page":"e00143","DOI":"10.1128\/JCM.00143-19","article-title":"Interaction between antibiotic resistance, resistance genes, and treatment response for urinary tract infections in primary care","volume":"57","author":"Ho","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2025052810022404000_ref34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ajem.2020.11.062","article-title":"Travel to Mexico and uropathogen-antibiotic susceptibility mismatch in the emergency department","volume":"46","author":"Torres","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2025052810022404000_ref35","doi-asserted-by":"crossref","first-page":"dlab003","DOI":"10.1093\/jacamr\/dlab003","article-title":"Antimicrobial resistance among uropathogens in the Asia-Pacific region: A systematic review","volume":"3","author":"Sugianli","year":"2021","journal-title":"JAC-Antimicrobial Resist"},{"key":"2025052810022404000_ref36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jgar.2024.08.013","article-title":"Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics","volume":"39","author":"Hawser","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"2025052810022404000_ref37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13756-023-01282-4","article-title":"Antibiotic treatment failure of uncomplicated urinary tract infections in primary care","volume":"12","author":"Koh","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025052810022404000_ref38","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s10096-019-03655-3","article-title":"Antibiotic resistance of Escherichia coli isolated from uncomplicated UTI in general practice patients over a 10-year period","volume":"38","author":"Driel","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025052810022404000_ref39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jgar.2018.11.004","article-title":"Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia","volume":"17","author":"Ny","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"2025052810022404000_ref40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ajem.2016.11.021","article-title":"Antimicrobial resistance in urinary tract infections at a large urban ED: Factors contributing to empiric treatment failure","volume":"35","author":"Rosa","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2025052810022404000_ref41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkad357","article-title":"Assessing the impact of discordant antibiotic treatment on adverse outcomes in community-onset UTI: A retrospective cohort study","volume":"79","author":"Aryee","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025052810022404000_ref42","doi-asserted-by":"crossref","first-page":"e0235921","DOI":"10.1128\/spectrum.02359-21","article-title":"Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible Enterobacter ales","volume":"10","author":"Dunne","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025052810022404000_ref43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajem.2017.06.041","article-title":"Risk factors for early return visits to the emergency department in patients with urinary tract infection","volume":"36","author":"Jorgensen","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2025052810022404000_ref44","doi-asserted-by":"crossref","first-page":"e0264722","DOI":"10.1128\/spectrum.02647-22","article-title":"Risk factors for carbapenem-resistant Enterobacterales clinical treatment failure","volume":"11","author":"Rebold","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025052810022404000_ref45","doi-asserted-by":"crossref","first-page":"e0256464","DOI":"10.1371\/journal.pone.0256464","article-title":"Risk factors for treatment failure in women with uncomplicated lower urinary tract infection","volume":"16","author":"Martischang","year":"2021","journal-title":"PloS One"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taaf025\/62801121\/taaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/4\/taaf025\/62801121\/taaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/32\/4\/taaf025\/62801121\/taaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:02:34Z","timestamp":1748440954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taaf025\/8099361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,28]]},"published-print":{"date-parts":[[2025,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taaf025","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"type":"print","value":"1195-1982"},{"type":"electronic","value":"1708-8305"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,28]]},"article-number":"taaf025"}}